CVS Caremark to cover Zepbound again after lawsuit, widespread backlash CVS Caremark is adding Zepbound, Eli Lillys blockbuster obesity drug, back to its commercial insurance plan formularies, more than a year after it stopped covering it in favor of Novo Nordisks Wegovy
The Core Issue: Failure to Warn Patients of Severe Risks The central argument in the GLP-1 lawsuits is that manufacturers like Novo Nordisk and Eli Lilly knew, or should have known, about the risk of severe side effects like stomach paralysis and bowel obstruction but failed to adequately warn doctors and patients
It is not a generic version of, nor equivalent to, any FDA-approved product
Deadlines to Stop Compounding, accessed February 2, 2026, Compounded GLP-1 Drugs: Texas Judge Denies PI Motion and Request for Stay of FDAs Declaration that Tirzepatide Shortage is Resolved
Ozempic (semaglutide), Wegovy (semaglutide), and compounded semaglutide works by: Slowing down digestion Enhances insulin secretion in response to increased blood sugar Stabilizing blood sugar levels These actions help keep your blood sugar more stable throughout the day
"There are so many people on these medications, but they won't speak up about [the side effects]," says Reilly